Price T Rowe Associates Inc Keros Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,514,505 shares of KROS stock, worth $29.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,514,505
Previous 1,187,910
27.49%
Holding current value
$29.4 Million
Previous $54.3 Million
62.0%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$48.8 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$36.9 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$36.1 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$29.6 Million7.2% of portfolio
-
State Street Corp Boston, MA1.11MShares$21.6 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $500M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...